ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2012
Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- Pooled it
- Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.Phytotherapy research : PTR · 2019Pooled it
- Trial
- A comprehensive review of recent advances in the extraction and therapeutic potential of berberine.RSC advances · 2025Review
- Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity.International journal of molecular sciences · 2024Article
- Herbal Products as Complementary or Alternative Medicine for the Management of Hyperglycemia and Dyslipidemia in Patients with Type 2 Diabetes: Current Evidence Based on Findings of Interventional Studies.Journal of nutrition and metabolism · 2024Review
- Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers.Pharmaceutics · 2023Article
- Role of Fenugreek, Cinnamon,Pharmaceuticals (Basel, Switzerland) · 2023Review
- Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial.Frontiers in pharmacology · 2023Article
- The role of selected nutraceuticals in management of prediabetes and diabetes: An updated review of the literature.Phytotherapy research : PTR · 2022Review
- Berberine in Non-Alcoholic Fatty Liver Disease-A Review.Nutrients · 2022Review
- Medicinal plants in the adjunctive treatment of patients with type-1 diabetes: a systematic review of randomized clinical trials.Journal of diabetes and metabolic disorders · 2020Review
- An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Phytopharmacology and Clinical Updates ofFrontiers in pharmacology · 2020Review
- Metformin and berberine, two versatile drugs in treatment of common metabolic diseases.Oncotarget · 2018Review
- Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in diabetic patients with dyslipidemia.Acta bio-medica : Atenei Parmensis · 2018Article
- The Pathogenesis of Diabetes Mellitus by Oxidative Stress and Inflammation: Its Inhibition by Berberine.Frontiers in pharmacology · 2018Review
- The Effects ofIranian journal of pharmaceutical research : IJPR · 2018Article
- Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis.Cholesterol · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuboptimal glycemic control is a common situation in diabetes, regardless of the wide range of drugs available to reach glycemic targets. Basic research in diabetes is endeavoring to identify new actives working as insulin savers, use of which could delay the introduction of injectable insulin or reduce the insulin dose needed. Commonly available as a nutraceutical, berberine is a potential candidate. METHODS AND
resultsBecause its low oral bioavailability can be overcome by P-glycoprotein inhibitors like herbal polyphenols, we have tested the nutraceutical combination of Berberis aristata extract and Silybum marianum extract (Berberol(®)) in type 2 diabetes in terms of its additive effect when combined with a conventional oral regimen for patients with suboptimal glycemic control. After 90 days of treatment, the nutraceutical association had a positive effect on glycemic and lipid parameters, significantly reducing glycosylated hemoglobin, basal insulin, homeostatic model assessment of insulin resistance, total and low-density lipoprotein cholesterol, and triglycerides. A relevant effect was also observed in terms of liver function by measuring aspartate transaminase and alanine transaminase. The product had a good safety profile, with distinctive gastrointestinal side effects likely due to its acarbose-like action.
conclusionAlthough further studies should be carried out to confirm our data, Berberol could be considered a good candidate as an adjunctive treatment option in diabetes, especially in patients with suboptimal glycemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.